Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gevokizumab + cabozantinib
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Gevokizumab + cabozantinib** is an investigational combination therapy combining gevokizumab, a recombinant humanized monoclonal antibody targeting interleukin-1 beta (IL-1β), with cabozantinib, a small molecule multi-tyrosine kinase inhibitor. Gevokizumab binds to and neutralizes IL-1β, mitigating pro-inflammatory pathways and potentially modulating the tumor immune microenvironment. Cabozantinib inhibits various receptor tyrosine kinases, including VEGFR-1, -2, and -3, MET, AXL, RET, KIT, FLT3, TIE2, and others, blocking tumor growth, metastasis, and angiogenesis. This combination is under early-stage clinical evaluation for solid tumors such as metastatic colorectal cancer, gastroesophageal cancer, and renal cell carcinoma, aiming to exploit synergistic anti-tumor and immunomodulatory effects[1][4][5][7].
- Other names
- gevokizumab + cabozantinib
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)AXL (AXL receptor tyrosine kinase)NTRK2 (Tropomyosin-related kinase receptor type B)KIT (c-KIT proto-oncogene receptor tyrosine kinase)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)TEK (Tie2)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on gevokizumab + cabozantinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gevokizumab + cabozantinib.